Basic leucine zipper transcriptional factor ATF-like (BATF)

Basic leucine zipper transcriptional factor ATF-like (BATF) is a critical member of the AP-1/ATF superfamily of transcription factors, primarily known for its essential role in orchestrating the differentiation and functional programs of various T-cell subsets, including Th17, Th9, and follicular T helper (Tfh) cells. Unlike many other members of the bZIP family, BATF lacks an intrinsic transactivation domain and frequently functions as a regulator by forming heterodimers with partners such as IRF4 to bind AP-1-IRF composite elements (AICE) in the genome. In the context of oncology, BATF is a dual-purpose therapeutic target; its high expression in tumor cells is often linked to increased proliferation and immune evasion (e.g., in cervical cancer), while its presence in T-cells is a hallmark of terminal exhaustion and impaired anti-tumor immunity. Current therapeutic research explores silencing BATF in tumor tissues to suppress growth or, conversely, overexpressing it in engineered CAR-T cells to prevent the metabolic and functional decline associated with chronic antigen exposure. Its central role in immune homeostasis also makes it a relevant target in autoimmune and inflammatory diseases where Th17-mediated pathology is prominent.

Other names

Basic Leucine Zipper Activating Transcription FactorB-ATFBATF1SFA-2B-cell-activating transcription factorSF-A2

BATF acts as a transcription factor that regulates immune cell fate and function; it typically forms heterodimers with partners such as IRF4 or JUN to bind specific DNA motifs. In cancer therapy, its inhibition in tumor cells aims to reduce proliferation and immune evasion, while its ectopic expression in CAR-T cells is utilized to prevent exhaustion and maintain cytotoxic activity.